April 23 (Reuters) - Novavax Inc NVAX.O:
NOVAVAX INC - TO ENGAGE WITH FDA TO ADDRESS PMC REQUEST - SEC FILING
NOVAVAX: "WE BELIEVE THAT OUR BLA IS APPROVABLE BASED ON CONVERSATIONS WITH FDA, AS OF OUR PDUFA DATE ON APRIL 1 AND THROUGH TODAY"
NOVAVAX INC - FDA REQUESTS POST MARKETING COMMITMENT FOR ADDITIONAL CLINICAL DATA FOR ITS COVID-19 VACCINE
Further company coverage: NVAX.O
((Reuters.Briefs@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。